Krystal Biotech Inc (KRYS)
Drugs • Health Care
August 03, 2026 Krystal Biotech Inc. Reports Strong Q2 2026 Results Amid Expanding Product Pipeline Krystal Biotech reported a significant revenue increase of $119.2 million in Q2 2026, driven by strong sales of its product VYJUVEK. The company is focused on expanding its pipeline in ophthalmology, dermatology, and respiratory diseases, reinforcing its commitment to innovation and growth.
August 03, 2026 Krystal Biotech Reports Strong Second Quarter 2026 Results, Highlights Robust Pipeline Krystal Biotech showcased impressive Q2 2026 results with $119.2 million in revenue from VYJUVEK, reflecting a 24% year-over-year increase. The company is transitioning towards becoming a multi-product genetic medicine powerhouse, with several promising therapies in its pipeline.
July 23, 2026 Krystal Biotech Set to Unveil Q2 2026 Financial Results Krystal Biotech will release its Q2 2026 financial results on August 3, 2026, with a conference call at 8:30 AM ET to discuss insights and company performance. The biotech firm is known for its pioneering work in genetic medicine, including the first redosable gene therapy, VYJUVEK®.
May 18, 2026 Krystal Biotech Receives UK Approval for VYJUVEK®: A Milestone in Dystrophic Epidermolysis Bullosa Treatment Krystal Biotech's VYJUVEK® has received UK approval as the first genetic treatment for dystrophic epidermolysis bullosa (DEB), targeting the root cause of the condition. The therapy delivers functional copies of the *COL7A1* gene, enhancing skin integrity and healing. With a robust clinical background and orphan designation, VYJUVEK is set to transform DEB treatment access in the UK.
May 07, 2026 Krystal Biotech to Showcase Innovations at BofA Securities 2026 Health Care Conference Krystal Biotech is set to present at the BofA Securities 2026 Health Care Conference on May 13, 2026. CEO Krish S. Krishnan will discuss advancements in genetic medicine, including their pioneering gene therapy, VYJUVEK®. The event will also feature investor engagement opportunities and a live webcast for wider accessibility.
May 04, 2026 Krystal Biotech Reports Strong Q1 2026 Financial Results and Business Update Krystal Biotech reported impressive Q1 2026 results with $116.4 million in product revenue, a 32% increase from last year. The company is expanding its market presence and advancing its clinical pipeline, including significant developments in ophthalmology and respiratory treatments.
May 04, 2026 Krystal Biotech Inc. Reports Strong Q1 2026 Results: VYJUVEK Sales Drive Growth Krystal Biotech reported strong Q1 2026 results with net product revenue of $116.4 million, driven by VYJUVEK sales. The company is expanding its market presence and pipeline of therapies across various therapeutic areas, positioning itself for future growth.
April 30, 2026 Krystal Biotech to Showcase Innovations at Upcoming Scientific Conferences Krystal Biotech is set to present its innovative gene therapy research at prominent scientific conferences in May and June 2026. Key highlights include presentations on treatments for primary ciliary dyskinesia and cystic fibrosis, showcasing the company's commitment to advancing genetic medicine.
April 21, 2026 Krystal Biotech Set to Release Q1 2026 Financial Results: Anticipation Builds Among Investors Krystal Biotech will release its Q1 2026 financial results on May 4, 2026, ahead of U.S. market opening. Investors are keen to learn about the company’s performance and strategic direction during the accompanying conference call.
February 24, 2026 Krystal Biotech to Showcase Innovations at TD Cowen 46th Annual Health Care Conference Krystal Biotech will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, highlighting its advancements in genetic therapies. The company will engage investors through a fireside chat and meetings, along with a webcast for broader access.
February 17, 2026 Krystal Biotech Reports Strong Financial Performance and Growth Prospects for 2025 Krystal Biotech reported impressive financial results for Q4 and full year 2025, with net product revenue increasing to $107.1 million. The company is expanding its offerings, particularly with VYJUVEK for rare diseases, while also advancing innovative treatments in respiratory and oncological areas.
February 17, 2026 Krystal Biotech Inc. Releases Strong 2025 Annual Report: A Year of Growth and Expansion Krystal Biotech Inc. reported a record $389.1 million in revenue for 2025, driven by the successful launch of its gene therapy VYJUVEK. The company is expanding its market presence while advancing a robust pipeline of genetic treatments, positioning itself for continued growth.
February 10, 2026 Krystal Biotech Set to Announce 2025 Financial Results Krystal Biotech is set to release its Q4 and full-year 2025 financial results on February 17, 2026. The announcement will be followed by a conference call detailing the company's financial performance and strategic initiatives, crucial for investors and stakeholders.
February 09, 2026 Krystal Biotech Secures RMAT Designation from FDA for KB707 in Lung Cancer Treatment Krystal Biotech has received RMAT designation from the FDA for its innovative therapy KB707, aimed at treating advanced non-small cell lung cancer. This designation accelerates development and signifies the potential for improved patient outcomes based on promising early clinical results.
January 11, 2026 Krystal Biotech Announces Strong Financial Performance and Strategic Vision at J.P. Morgan Healthcare Conference Krystal Biotech showcased strong financial performance and a strategic vision for rare diseases during the J.P. Morgan Healthcare Conference. With a successful product launch and ambitious pipeline expansion plans, the company aims to become a leader in the rare disease market.
January 08, 2026 Krystal Biotech Reports Breakthrough in Cystic Fibrosis Treatment with KB407 Krystal Biotech's Phase 1 CORAL-1 study reveals positive interim results for the cystic fibrosis treatment KB407, demonstrating effective delivery of CFTR protein. The study highlights significant breakthroughs for patients, particularly those ineligible for existing therapies.
January 07, 2026 Krystal Biotech Set to Reveal Interim Clinical Update on KB407 in Cystic Fibrosis Study Krystal Biotech is set to provide an interim clinical update on its cystic fibrosis treatment KB407 during a conference call on January 8, 2026. The CORAL-1 study aims to evaluate the safety and efficacy of KB407, with significant insights expected that could impact the cystic fibrosis community.
January 05, 2026 Krystal Biotech to Showcase Innovations at J.P. Morgan Healthcare Conference Krystal Biotech will present at the J.P. Morgan Healthcare Conference on January 12, 2026, highlighting innovations in genetic medicine and engaging with investors. The company is known for its first redosable gene therapy, VYJUVEK®, and has a robust pipeline of products addressing various medical needs.
November 26, 2025 Krystal Biotech Set to Shine at Evercore Healthcare Conference Krystal Biotech will showcase its advancements in genetic therapies at the Evercore Healthcare Conference on December 3, 2025. CEO Krish S. Krishnan will engage in a fireside chat, highlighting the company's innovative approaches and future strategies.
November 03, 2025 Krystal Biotech Reports Strong Q3 2025 Results and Expands Global Reach Krystal Biotech reported a 16.5% increase in Q3 2025 revenue, driven by VYJUVEK's expanding patient access and reimbursement approvals. The company is also actively launching its therapy internationally and advancing its innovative pipeline in various therapeutic areas, positioning itself for continued growth.
November 03, 2025 Krystal Biotech Inc. Reports Strong Q3 Performance for 2025 Krystal Biotech Inc. reports strong Q3 2025 results, driven by VYJUVEK's market success. The company shows robust revenue growth and a promising pipeline in genetic medicine.
October 21, 2025 Krystal Biotech Set to Report Q3 2025 Financial Results Krystal Biotech is set to report its Q3 2025 financial results on November 3, 2025. The announcement will be followed by a conference call to discuss the company’s performance and future strategies, highlighting its groundbreaking work in genetic medicine.
October 14, 2025 Krystal Biotech Secures FDA Platform Technology Designation for Innovative Gene Therapy Krystal Biotech has received FDA platform technology designation for its gene therapy KB801, aimed at treating neurotrophic keratitis. This milestone promises expedited development processes and improved treatment options for patients. The therapy focuses on reducing the treatment burden associated with current methods.
August 04, 2025 Krystal Biotech Inc. Reports Strong Q2 2025 Results, Highlights Growth in Genetic Medicine Krystal Biotech Inc. has reported a significant revenue increase in Q2 2025, largely attributed to its gene therapy VYJUVEK. With a robust financial position and expanding pipeline, the company is poised for continued growth in genetic medicine.
May 06, 2025 Krystal Biotech Inc. Reports Impressive Q1 2025 Financial Results Krystal Biotech Inc. reported significant growth in Q1 2025, with revenues soaring to $88.2 million, driven by the success of its FDA-approved product VYJUVEK. The company continues to innovate in genetic therapies, addressing critical unmet medical needs across various therapeutic areas.
February 28, 2025 Krystal Biotech Inc. Celebrates Positive CHMP Opinion for VYJUVEK® Approval Krystal Biotech celebrates a positive recommendation from the CHMP for VYJUVEK®, a groundbreaking gene therapy for dystrophic epidermolysis bullosa. This treatment, which can be administered at home, shows promise in transforming patient care and is set for potential approval by the European Commission in 2025.
February 26, 2025 Krystal Biotech to Showcase Innovations at TD Cowen 45th Annual Health Care Conference Krystal Biotech will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, showcasing its advancements in genetic therapies. CEO Krish S. Krishnan will lead discussions on the company's strategic direction and ongoing initiatives. A webcast will also be available for wider audience access.
February 19, 2025 Krystal Biotech Reports Strong Financial Growth and Strategic Advances in 2024 Krystal Biotech reported significant revenue growth in 2024, driven by its flagship product VYJUVEK, with plans for global expansion and innovative clinical programs. The company achieved a 95% gross margin and high patient compliance, signaling strong market acceptance. With ongoing advancements in ophthalmology and oncology, Krystal is well-positioned for a promising future.
February 19, 2025 Krystal Biotech Inc. Reports Strong 2024 Financial Results Driven by VYJUVEK Sales Krystal Biotech Inc. reported remarkable financial results for 2024, with net revenues soaring to $290.5 million, primarily from its FDA-approved gene therapy VYJUVEK. The company's strong gross margin of 93% and solid balance sheet position highlight its effective commercialization strategy and growth potential in the biotechnology sector.
February 06, 2025 Krystal Biotech Set to Release Financial Results for Q4 and Full Year 2024 Krystal Biotech, Inc. will announce its Q4 and full-year 2024 financial results on February 19, 2025. A conference call will follow to discuss insights and updates on its innovative genetic therapies.
January 30, 2025 SWOT Analysis of Krystal Biotech Inc in 2025 This SWOT analysis of Krystal Biotech Inc for 2025 evaluates its strengths like first-mover advantage with VYJUVEK and robust technology, while addressing weaknesses and threats from competition. It also explores opportunities for market expansion and partnerships, essential for overcoming challenges in the biotechnology sector.
November 04, 2024 Krystal Biotech Inc. Reports Robust Q3 2024 Financial Results Krystal Biotech Inc. reported a robust Q3 2024, achieving a net income of $27.18 million, a remarkable turnaround from last year. The company's flagship product, VYJUVEK, contributed significantly to revenue growth, showcasing a 92% gross margin and strong pipeline prospects in genetic and aesthetic medicine.
May 06, 2024 Krystal Biotech Inc. Reports Strong Q1 2024 Results Krystal Biotech Inc. reported impressive Q1 2024 results, with $45.3 million in revenue from VYJUVEK. The company shows strong financial health and a promising product pipeline, indicating potential for continued growth.